{"id":"W2608337225","doi":"10.1097/01.cot.0000516713.11719.72","title":"Phase III SOLO-2 Data Demonstrates High Survival Benefit of Olaparib","year":2017,"lang":"en","type":"article","venue":"Oncology Times","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Olaparib; Tolerability; Medicine; Oncology; Internal medicine; Ovarian cancer; Clinical endpoint; BRCA mutation; Placebo; PARP inhibitor; Clinical trial; Cancer; Adverse effect; Pathology; Biology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001740838,0.0008453529,0.001486105,0.0003705218,0.0003139147,0.001180463,0.0005720551,0.001207762,0.00909284],"category_scores_gemma":[0.001906367,0.0004044377,0.001572592,0.0004040354,0.0006034151,0.0006887236,0.0003009814,0.002777515,0.001171315],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000530749,"about_ca_system_score_gemma":0.001025169,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002964569,"about_ca_topic_score_gemma":0.001254486,"domain_scores_codex":[0.9994981,0.000268262,0.00003707752,0.00006941686,0.0000740324,0.00005313774],"domain_scores_gemma":[0.9988273,0.0003940914,0.0002813698,0.0001370415,0.00009124961,0.0002689752],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6237365,0.02298495,0.004319425,0.003413974,0.002665621,0.0003075581,0.0001941356,0.001128344,0.05656603,0.001020576,0.03078177,0.2528811],"study_design_scores_gemma":[0.8220925,0.1293796,0.00795516,0.0002838477,0.001390915,0.0007033865,0.00005160925,0.001099063,0.01191651,0.0008188635,0.02425791,0.00005056096],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9315389,0.02825721,0.002845743,0.007207379,0.001280949,0.00558835,0.008574894,0.0006507454,0.01405588],"genre_scores_gemma":[0.959529,0.01019425,0.004190856,0.005202872,0.0007654406,0.003897507,0.008211118,0.000162539,0.007846341],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00909284,"threshold_uncertainty_score":0.03041857,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09102410319965419,"score_gpt":0.4192331876939281,"score_spread":0.3282090844942739,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}